CDT Equity (CDT) Tax Provisions (2022 - 2023)
CDT Equity's (CDT) quarterly Tax Provisions came in at $212735.0 in Q2 2023, up 616.18% YoY from $29704.0 in Q2 2022, and up 481.93% on a QoQ basis from $36557.0 in Q1 2023.
CDT Equity (CDT) Tax Provisions (2022 - 2023) Analysis & Trends
CDT Equity (CDT) has 2 years of Tax Provisions data on file, last reported at $212735.0 in Q2 2023.
- Quarterly Tax Provisions rose 616.18% year-over-year to $212735.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $594450.0 (changed N/A YoY) and the FY2022 annual result came in at $374862.0, changed N/A from the prior year.
- Tax Provisions improved to $212735.0 in Q2 2023, from $36557.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $212735.0 in Q2 2023 to a low of $29704.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | - |
| 10 | CDT Equity | 1.59 Mn | 1.59 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 212,735.00 |
| Mar 31, 2023 | 36,557.00 |
| Dec 31, 2022 | 188,504.00 |
| Sep 30, 2022 | 156,654.00 |
| Jun 30, 2022 | 29,704.00 |